Patient Capital Sees Long-Term Potential in Chime
The investment strategy highlighted Chime as a top-ten holding and said its low-cost banking model could support long-term growth.
Key takeaways
- Patient Capital said it continued to accumulate Chime shares.
- The strategy estimated Chime was worth $47 in its Q3 letter.
Patient Capital Management described Chime Financial as a long-term compounder in its third-quarter 2026 investor letter, saying it had continued to accumulate shares. The strategy named Chime as its final top-ten holding.
The strategy said Chime’s low-cost primary banking relationships and brand could support its long-term potential. It also said Chime adds more new checking account relationships than any other bank, including Chase and Bank of America.
Patient Capital estimated Chime was worth $47, which it described as 68% above the $28.96 price cited in the letter. Chime shares recently traded at $30.37, up 0.96% since the previous close, as of Monday afternoon.
This article was produced with the help of AI technology. Source: Yahoo Finance
